Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Gets Senate Funding, House Scolding In FY 2015 CR-Omnibus

This article was originally published in The Pink Sheet Daily

Executive Summary

Spending agreement would give FDA about a 1.3% increase from the fiscal year 2014 enacted appropriations legislation.

You may also be interested in...



Ebola Treatments Could Be Orphan Candidates – But Vaccines, Probably Not

FDA expects few people would get the disease in the U.S., but many could receive a vaccine.

FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling

Draft guidance on abuse-deterrent opioids notes that labeling claims may be revised if abusers outwit the abuse-resistant technology; the agency’s evaluation of generic-related citizen petitions continues.

US FDA Likely To Embrace In-Person, Remote Combo For Facility Inspections Going Forward

The system likely will evolve as the post-pandemic world unfolds, but adds to the list of agency programs expecting to continue using virtual platforms once in-person activities are no longer restricted by COVID-19.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS076723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel